Zogenix To Present New Long-term Data On FINTEPLA (fenfluramine) In Lennox-Gastaut Syndrome (LGS) At AAN 2022 From April 2-7

Author: Benzinga Newsdesk | March 04, 2022 09:06am

Zogenix (NASDAQ:ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).

"At AAN, we look forward to sharing our latest research for FINTEPLA in LGS that highlights long-term evidence of its cardiovascular safety profile as well as sustained reduction in drop seizure frequency," said Bradley S. Galer, M.D., Executive Vice President and Chief Medical Officer, Zogenix. "Additionally, we are encouraged by compelling findings in the improvement of everyday executive functioning, which is a critical measure for physicians, patients and caregivers managing this challenging condition. Collectively, this research underscores our enduring commitment to addressing the unmet treatment needs in LGS."

The analyses include the FINTEPLA open-label study data (NCT03355209) in LGS at two podium presentations, and authors will be available to discuss the data during a discussion:

• Interim Analysis of Long-Term Safety and Efficacy of FINTEPLA (fenfluramine) in Patients with Lennox-Gastaut Syndrome
  
  Knupp, Scheffer, Ceulemans, et al.
  
  Session S13: Epilepsy/Clinical Neurophysiology (EEG): Antiseizure Medications
  
  Authors available: Monday, April 4, 2022, at 2:48 PM PT

• Long-Term Cardiovascular Safety of Fenfluramine for Lennox-Gastaut Syndrome: Interim Analysis of Open-Label Safety Study
  
  Agarwal, Farfel, Gammiatoni, et al.
  
  Session S24: Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy
  
  Authors available: Tuesday, April 5, 2022, at 4:18 PM PT

A poster will also be presented about the impact of FINTEPLA on everyday executive function in patients, as captured using the Behavior Rating Inventory of Executive Function (BRIEF®).

• Fenfluramine Improves Everyday Executive Functioning in Patients With Lennox-Gastaut Syndrome: Analysis of Phase 3 Data
  
  Bishop, Isquith, Gioia, et al.

The abstracts being presented are available on the AAN website and will be available following the meeting on the Zogenix Newsroom site.

Posted In: ZGNX